STOCK TITAN

Flora Growth Corp. (NASDAQ: FLGC) appoints independent director and reshapes key board committees

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Flora Growth Corp. reported board and committee changes. On January 6, 2026, the board unanimously appointed Larry Zeifman as a director, as a member of the audit, compensation, and nominating and corporate governance committees, and as Chair of the Audit Committee. The board also named Manfred Leventhal as Chair of the nominating and corporate governance committee.

The board determined that Mr. Zeifman is an independent director who meets Nasdaq and SEC standards for audit and compensation committee service. His appointment fills vacancies created by the passing of director Harold Wolkin on August 25, 2025. The company states there are no special arrangements, family relationships, or related-party transactions tied to Mr. Zeifman’s appointment, and no material compensation plan or award has been granted in connection with his joining the board.

Positive

  • None.

Negative

  • None.

false 2026-01-05 0001790169 00-0000000 Flora Growth Corp. 0001790169 2026-01-05 2026-01-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2026

FLORA GROWTH CORP.
(Exact name of registrant as specified in its charter)

Ontario 001-40397 Not Applicable
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

3230 W. Commercial Boulevard, Suite 180
Fort Lauderdale, Florida, United States 33309
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (954) 842-4989

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbols   Name of each exchange on
which registered
Common Shares, no par value   FLGC   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 6, 2026, the board of directors (the "Board") of Flora Growth Corp. (the "Company") unanimously approved by written consent the appointment of (i) Mr. Larry Zeifman as a director of the Company, as a member of the audit committee of the Board (the "Audit Committee"), as a member of the compensation committee of the Board (the "Compensation Committee"), as a member of the nominating and corporate governance committee of the Board (the "Nominating Committee") and as Chair of the Audit Committee and (ii) Mr. Manfred Leventhal as Chair of the Nominating Committee.

The Board has determined that Mr. Zeifman is an independent director, meets the applicable standards for Audit Committee service under both the Nasdaq Stock Market Rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and meets the applicable standards for Compensation Committee service under the Nasdaq Stock Market Rules. Mr. Zeifman's appointment fills the vacancy on the Board, the Compensation Committee and the Nominating Committee which resulted from the passing of Harold Wolkin on August 25, 2025.

There are no arrangements or understandings between Mr. Zeifman and any other persons pursuant to which Mr. Zeifman was selected as a director of the Company. There are no family relationships between Mr. Zeifman and any of the Company's other directors or executive officers and Mr. Zeifman does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

There is no material plan, contract or arrangement (whether or not written) entered into between the Company and Mr. Zeifman relating to his appointment to the Board, and, as of this Current Report, Mr. Zeifman has not received any grant or award or any modification thereto under any such plan, contract or arrangement in connection with his appointment.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  FLORA GROWTH CORP.  
       
Date: January 6, 2026 By: /s/ Dany Vaiman  
  Name: Dany Vaiman  
  Title: Chief Financial Officer  


FAQ

What board changes did Flora Growth Corp. (FLGC) disclose?

Flora Growth Corp. disclosed that its board appointed Larry Zeifman as a director, as a member of the audit, compensation, and nominating and corporate governance committees, and as Chair of the Audit Committee. The board also appointed Manfred Leventhal as Chair of the nominating and corporate governance committee.

Is the new Flora Growth (FLGC) director considered independent?

The board determined that Larry Zeifman is an independent director. It stated that he meets applicable standards for audit committee service under Nasdaq rules and Rule 10A-3 under the Exchange Act, and for compensation committee service under Nasdaq rules.

Why did Flora Growth (FLGC) have a vacancy on its board and committees?

The company explained that Mr. Zeifman’s appointment fills vacancies on the board, compensation committee, and nominating and corporate governance committee that arose following the passing of director Harold Wolkin on August 25, 2025.

Are there any related-party relationships tied to Flora Growth’s new director?

Flora Growth stated there are no arrangements or understandings with other persons related to Mr. Zeifman’s selection, no family relationships between him and other directors or executive officers, and no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.

Did Flora Growth (FLGC) agree to any compensation plan for Larry Zeifman upon appointment?

The company noted there is no material plan, contract, or arrangement between Flora Growth and Mr. Zeifman relating to his appointment to the board, and that, as of the report date, he had not received any grant, award, or modification under such arrangements in connection with his appointment.

What stock exchange is Flora Growth Corp. (FLGC) listed on?

Flora Growth Corp.’s common shares, with no par value, trade under the symbol FLGC on the Nasdaq Capital Market.

Flora Growth Corp

NASDAQ:FLGC

FLGC Rankings

FLGC Latest News

FLGC Latest SEC Filings

FLGC Stock Data

6.84M
610.38k
12.54%
4.08%
1.14%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
FORT LAUDERDALE